Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505514-15-00

Enrollment

310

Registered

2023-11-29

Start date

2022-01-11

Completion date

Unknown

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extensive stage, Small-cell lung cancer

Brief summary

1-year overall survival

Detailed description

2-year, 3-year, 4-year and 5-year overall survival, Overall response rates, Response rates in non-irradiated lesions, Progression free survival, Progression free survival in non-irradiated lesions, Local control rates in the thorax, Frequency and severity of adverse events, Health-related quality of life

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1-year overall survival	—

Secondary

Measure	Time frame
2-year, 3-year, 4-year and 5-year overall survival, Overall response rates, Response rates in non-irradiated lesions, Progression free survival, Progression free survival in non-irradiated lesions, Local control rates in the thorax, Frequency and severity of adverse events, Health-related quality of life	—

Countries

Estonia, Iceland, Netherlands, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026